Somatostatin analogues in the treatment of endocrine tumours of the gastrointestinal tract

Bibliography

• SOLCIA E, KLOPPEL G, SOBIN LH et al: Histological typing of endocrine tumours. In: International Histological Classification of Tumours Second Edition. World Health Organization. Springer Verlag Berlin Heidelberg, New York (2000). ISBN 3-540-66169–7.
   Google Scholar
• ••Comprehensive review on tumourpathology.
   Google Scholar
• CALENDAR A: Molecular genetics of neuroendocrine tumours. Digestion (2000) 62\(Suppl. 1):3–18.
   Google Scholar
• •Detailed review on molecular genetics.
   Google Scholar
• RINDI G, AZZONI C, LA ROSA S et al: ECL cell tumour and poorly differentiated endocrine carcinoma of the stomach: prog-nostic evaluation by pathological analysis. Gastroenterology (1999) 116:532–542.
   PubMed Web of Science ®Google Scholar
• •Evaluation of histological and prognostic factors.
   Google Scholar
• MOERTEL CG, KVOLS LK, O'CONNELL MJ, RUBIN J et al.: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer (1991) 68:227–232.
   Google Scholar
• •Impact of tumour differentiation on chemotherapy efficacy.
   Google Scholar
• GOLDSTONE AP, SCOTT-COMBES DM, LYNN SA et al: Surgical management of gastrointestinal tumours. In: Gastrointestinal Endocrine Tumours. Baillere's Clinical Gastroenterology (2000) 10\(Number 4):707–734.
   Google Scholar
• •A thorough review on surgery.
   Google Scholar
• PRAYE C: Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumours: place for chemoembolization. World J. Surg (2001) 25:685–688.
   PubMedGoogle Scholar
• RUSZNIEWSKY P, MALKA D: Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Digestion (2000) 62\(Supp1.1):79–83.
   Google Scholar
• FRILLING A, ROGIERS X, MALAGO M, LIEDKE O, KAUN M, BROELSCH LE et al: Liver transplantation in patients with liver metastases of neuroendocrine tumours. Transplant. Proc. (1998) 30:3298–3300.
   PubMedGoogle Scholar
• ROUTLEY D, RAMAGE JK, PEAKE J, TAN KC, WILLIAMS R et al.: Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumours of the liver. Liver TranspL Surg (1995) 1:118–121.
   PubMedGoogle Scholar
• MOERTEL CG, LEFKOPOULOS M, LIPSITZ M et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil of chlorozotocin in the treatment of advanced islet-cell carcinoma. N EngL J. Med. (1992) 326:519–523.
   PubMed Web of Science ®Google Scholar
• •Impact of chemotherapy on survival in patients with pancreatic endocrine tumours.
   Google Scholar
• BRAZEAU P, VALE W, BURGUS R et al.: Hypothalamic polypeptide that inhibits the secretion of immunoreative pituitary growth hormone. Science (1973) 179:77–79.
   PubMed Web of Science ®Google Scholar
• ••First description of somatostatin.
   Google Scholar
• PRADAYROL L, JORNVALL H, MUTT V et al: N-terminally extended somatostatin: the primary structure of somatostatin 28. FEBS Lett. (1980) 109:55–58.
   PubMed Web of Science ®Google Scholar
• EPELBAUM J, DOURNAUD P, FODOR Met al.: The neurobiology of somatostatin. Grit. Rev. NeurobioL (1994) 8:25–44.
   PubMedGoogle Scholar
• LAMBERTS SWS, VAN DER LELY AJ, DE HERDER WW, HOFLAND LS: Octreotide. NEM (1996) 334:246–254.
   PubMedGoogle Scholar
• ••A comprehensive review of thesomatostatin analogue octreotide.
   Google Scholar
• BENALI N, FERJOUX G, PAENTE E et al.: Somatostatin receptors. Digestion (2000) 62(Suppl. O:27–32.
   Google Scholar
• ••A comprehensive review of somatostatinreceptors.
   Google Scholar
• REISINE T, BELL GI: Molecular biology of somatostatin receptors. Endocr. Rev. (1995) 6:427–442.
   Google Scholar
• •A thorough review of somatostatin receptor biology.
   Google Scholar
• BRUNS C, WECKBECKER G, RAULF F et al.: Characterization of somatostatin receptor subtypes. CIBA Found. Symp. (1995) 190:89–101.
   PubMedGoogle Scholar
• BUSCAIL L, ESTEVE JP, SAINT-LAURENT et al.: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. USA (1995) 92:1580–1584.
   PubMed Web of Science ®Google Scholar
• SHARMA K, PATEL YC, SRIKANT CB et al.: C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol. Endocrinol. (1999) 13:82–90.
   PubMed Web of Science ®Google Scholar
• ALDERTON F, FAN TP, SCHINDLER M, HUMPHREY PP: Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation. Br. J Pharmacol. (1998) 125:1630–1633.
   PubMedGoogle Scholar
• BUSCAIL L, DELESQUE N, ESTEVE JP et al.: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc. Natl. Acad. Sci. USA (1994) 91:2315–2319.
   PubMed Web of Science ®Google Scholar
• FLORIO T, YAO H, CAREY KD et al.: Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. (1999) 13:24–37.
   PubMed Web of Science ®Google Scholar
• CORDELIER P, ESTEVE JP, BOUSQUET C et al.: Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc. Natl. Acad. Sci. USA (1997) 94:9343–9348.
   PubMed Web of Science ®Google Scholar
• BOUSQUET C, DELESQUE N, LOPEZ F et al.: sst2 somatostatin receptor mediates negative regulation of insulin receptor signalling through the tyrosine phosphatase Shp-1.J. Biol. Chem. (1998) 273:7099–7106.
   Google Scholar
• PAGES P, BENALI N, SAINT-LAURENT N et al.: sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of Shp-1. J. Biol. Chem. (1999) 274:15186–15193.
   Google Scholar
• SHARMA K, SRIKANT CB: Induction of wild type p53, Box and acidic endonuclease during somatostatin-signalled apoptosis in MCF-7 human breast cancer cells. Int. J. Cancer (1998) 76:259–266.
   PubMed Web of Science ®Google Scholar
• ROCHAIX P, DELESQUE N, ESTEVE JP et al.: Gene therapy for pancreatic carcin-oma: local and distant antitumour effects aft er somatostatin receptor sst2 gene transfer. Hum. Gene Ther. (1999) 10:995–1008.
   PubMed Web of Science ®Google Scholar
• REUBI JC, KVOLS LK, WASER B et al.:Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. (1990) 50:5969–5977.
   PubMed Web of Science ®Google Scholar
• REUBI JC, KRENNING E, LAMBERTS SW, KVOLS L: In vitro detection of somatostatin receptors in human tumours. Metabolism (1992) 41:104–110.
   PubMedGoogle Scholar
• REUBI JC, LAISSUE J, KRENNING E, LAMBERTS SW: Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications./ Steroid Biochem. Mol. Biol. (1992) 43:27–35.
   PubMed Web of Science ®Google Scholar
• REUBI JC, SCHAER JC, WASER B, MENGOD G: Expression and localization of somatostatin receptors SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumours using in situ hybridization. Cancer Res. (1994) 54:3455–3459.
   PubMed Web of Science ®Google Scholar
• SCHAER JC, WASEN B, MENGOLD G, REUBI SC: Somatostatin receptor subtypes sstl, sst2, sst3 and sst5 expression in human pituitary, gastroenteropancreatic and mammary tumours: comparison of mRNA analysis with receptor autoradiography. Int. J. Cancer (1997) 70:530–537.
   PubMed Web of Science ®Google Scholar
• VAN EIJCK C, KWEKKEBOOM DJ, KRENNING EP: Somatostatin receptors and breast cancer. Quart J. Nucl. Med. (1998) 42:18–25.
   PubMedGoogle Scholar
• JANSON ET, STIDSBERG M, GOBL A et al.: Determination of somatostatin receptor subtype 2 in carcinoid tumours by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res. (1998) 58:2375–2378.
   PubMed Web of Science ®Google Scholar
• KIMURA N, PILICHOWSKA M, DATE F et al.: Immunohistochemical expression of somatostatin Type 2A receptor in neuroendocrine tumours. Clin. Cancer Res. (1999) 5:3483–3487.
   PubMedGoogle Scholar
• KULAKSIZ H, EISSELE R, ROESSLER Det al.: Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype-specific antibodies. Gut (2002) 50:52–60.
   Google Scholar
• WULBRAND U, REMMERT G, ZOFEL P et al.: mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur. j Clin. Invest. (2000) 30:729–739.
   PubMedGoogle Scholar
• KRENNING EP, KWEKKEBOOM DJ, BAKKER WH et al.: Somatostatin receptor szintigraphy with [111In-DTPA-D-Phel]-and[123I-Tyr3]-octreotide. The Rotterdam experience with more than 1000 patients. EurJ. Nuc. Med. (1993):20: 716–731.
   Google Scholar
• ••A detailed evaluation of somatostatinreceptor scintigraphy.
   Google Scholar
• LEBTAHI R, CADIOT G, SARDA L et al.: Clinical impact of somatostatin receptor szintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumours.J. Nue/. Med. (1997) 38:853–858.
   PubMed Web of Science ®Google Scholar
• ••A detailed evaluation of somatostatinreceptor scintigraphy.
   Google Scholar
• WEBER HC, VENZON DJ, LIN JT et al.: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology (1995) 108:1637–1649.
   PubMed Web of Science ®Google Scholar
• GIBRIL F, REYNOLDS SC, DOPMAN JC et al.: Somatostatin receptor szintigraphy compared with that of other imaging methods in detecting primary and metastatic gastrinomas - a prospective study. Ann. Intern. Med. (1996) 125:26–34.
   PubMed Web of Science ®Google Scholar
• GIBRIL F, REYNOLDS JC, CHEN CC et al.: Specificity of somatostatin receptor szintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinoma. Nucl. Med. (1999) 40:539–554.
   Google Scholar
• SCHEROBL H, WIEDENMANN B, RIECKEN EO et al.: Treatment of carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur. J. Cancer (1994) 10:1591–1592.
   Google Scholar
• RUSZNIEWSKI P, DUCREUX M, CHAGVIALLE JA et al.: Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut (1996) 39:279–283.
   PubMed Web of Science ®Google Scholar
• COLAO A, FERONE D, MARZULLO et al.: Long-term effects of depot-acting somatostatin analog on hormone levels and
   Google Scholar
• •• tumour mass in acromegaly. j Gun. EndocrinoL Metab. (2001) 86:2779–2786.
   Google Scholar
• KENDALL-TAYLOR P, MILLER M, GEBBIE et al: Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary (2000) 3:61–65.
   PubMedGoogle Scholar
• CHANSON P, BOERLIN V, AJZENBERG C et al: Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Gun. EndocrinoL (2000) 53:577–586.
   Google Scholar
• •Equipotency of octreotide and lanreotide.
   Google Scholar
• CORLEY DA, CELLO PJ, ADKISSON W et al.: Octreotide for acute variceal bleeding: a meta-analysis. Gastroenterology (2001) 120:946–954.
   PubMed Web of Science ®Google Scholar
• IMPERIALE TF, TERAN JF, MCCULLOUGH AJ: A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology (1995) 109:1289–1294.
   PubMed Web of Science ®Google Scholar
• KHOO D, HALL E, MOTSON R et al: Palliation of malignant intestinal obstruction using octreotide. Eur. j Cancer (1994) 30:28–30.
   Google Scholar
• WADLER S, BENSON AB, ENGELKING C et al.: Recommended guide lines for the treatment of chemotherapy-induced diarrhea. J. Clin. OncoL (1998) 16:3169–3171.
   PubMed Web of Science ®Google Scholar
• KVOLS LK, MOERTEL G, O'CONNEL MJ et al.: Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N EngL Med. (1986) 315:663–666.
   Google Scholar
• VINIK A, MOATTARI AR: Use of somatostatin analog in the management of carcinoid syndrome. Dig Dis. Sci. (1998) 34(Suppl.):149–275.
   Google Scholar
• ARNOLD R, TRAUTMANN ME, CREUTZFELDT Wet al.: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 38:430–438.
   Google Scholar
• RUBIN J, AJANI J, SCHIRMER W et al:Octreotide acetate long-acting formulation versus open-labelled subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. OncoL (1999) 17:600–606.
   PubMed Web of Science ®Google Scholar
• •Equipotency of long-acting formulation with short-lasting octreotide.
   Google Scholar
• O'TOOLE D, DUCREUX M, BOMMELAER Get al.: Treatment of carcinoid syndrome. A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability and tolerance. Cancer (2000) 88:770–776.
   Google Scholar
• •Equipotency of octreotide and lanreotide.
   Google Scholar
• WOOD DM, KRAENZLIN MW, ADRIAN TE, BLOOM SM: Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue: symptomatic and peptide responses. Gut (1985) 25:438–444.
   Google Scholar
• RUSKONE. A, RENE E, CHAYVIALLE JA et al.: Effect of somatostatin on diarrhea and on small intestine water and electrolyte transport in a patient with pancreatic cholera. Dig Dis. Sci. (1982) 27:459–466.
   Google Scholar
• MATON PN, O'DORISIO TM, HOWE BA et al.: Effect of long-acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera. N EngL J Med. (1985) 312:17–21.
   Google Scholar
• SANTANGELO WC, O'DORISIO TH, KIM JG et al.: Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann. Intern. Med. (1985) 103:363–367.
   Google Scholar
• CH'NG JL ANDERSON JV, WILLIAMSSJ, CARR DH, BLOOM SR: Remission of symptoms during long-term treatment of metastatic pancreatic endocrine tumours with long-acting somatostatin analogue. Br. Med. J. (1986) 292:981–982.
   Google Scholar
• ROSENBAUM A, FLOURIE B, CHAGNON S, BLERY M, MODIGLIANI R: Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Digestion (1989) 42:116–120.
   PubMedGoogle Scholar
• GUILLAUSSEAU PJ, GUILLAUSSEAU-SCHOLER C: Glucagonomas: clinical presentation, diagnosis and advances in management. In: Endocrine Tumours of the Pancreas. Mignon M, Jensen RT (Eds), Front Gastrointestinal Research. Basel, Karger (1995) 23:183–193.
   Google Scholar
• BARKAN AL, SHENKER Y, GREKIN RJ et al.: Acromegaly due to ectopic growth hormone (GH)-releasing hormone (GHRH) production: dynamic studies of GH and ectopic GHRH secretion. J EndocrinoL Metab. (1986) 63:1057–1064.
   Google Scholar
• MELMED S, ZIEL FH, BRAUNSTEIN GD et al.: Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumour. J. Clin. EndocrinoL Metab. (1988) 67:395–399.
   PubMedGoogle Scholar
• MATON PN, GARDNER JD, JENSEN RT: Use of long-acting somatostatin analogue SMS 201–995 in patients with pancreatic islet cell tumours. Dig Dis. Sci. (1989) 34(Suppl.):285–291.
   Google Scholar
• FAJANS SS, VINIK Al: Insulin-producingislet cell tumours. Endo. Metab. Gun. N Am. (1989) 18:45–74.
   PubMed Web of Science ®Google Scholar
• RUSZNIEWSKI P, GIRARD F, BENAMOUZIG R et al.: Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome. Gut (1988) 29:838–842.
   PubMedGoogle Scholar
• BURREL L, GREY CE, THOMSON SA. Failure of somatostatin analogue SMS 201–995 to control Cushing's syndrome due to ectopic release of ACTH from a bronchial carcinoid. Scott Med. J (1989) 34:533–534.
   Google Scholar
• CREUTZFELDT W, ARNOLD R, CREUTZFELDT C, TRACK RS: Pathomorphologic, biochemical and diagnostic aspects of gastrinoma (Zollinger-Ellison syndrome). Hum. PathoL (1975) 6:47–76.
   PubMed Web of Science ®Google Scholar
• METZ D, JENSEN RT: Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Endocrine Tumours of the Pancreas. Recent Advances in Research and Management. Mignon M, Jensen RT (Eds), Front Gastrointestinal Research. Basel, Karger (1995) 23:240–257.
   Google Scholar
• WYMENGA ANM, ERIKSSON B, SALMELA PI et al.: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumours and hormone related symptoms. J. OncoL (1999) 17:1111–1117.
   Google Scholar
• ERIKSSON B, OBERG K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumours: future outlook. Ann. OncoL (1999) 10\(Suppl. 2):31–38.
   Google Scholar
• ••A thorough review of somatostatinanalogue therapy.
   Google Scholar
• GEYPENS BH, GHOOS Y, RUTGEERTS P: Pharmacological modulation of orocecal transit by antidiarrheals monitored by the lactose-(VC) ureide breath test. Gastroenterology (1999) 116:A997.
   Google Scholar
• MURAO S, HIRATE K, ISHIDA T, TAKAHARA J: Severe diabetic diarrhea successfully treated with octreotide, a somatostatin analogue. Endocrine Journal (1999) 46:477–478.
   PubMedGoogle Scholar
• FAROOQI JI, FAROOQI RJ: Role of octreotide in chemo- and radiotherapy-induced diarrhea. J Coll. Phys. Surg Pakistan (2000) 10:93-94. Expert Op/n. Pharmacother (2002) 3(6)
   Google Scholar
• IPPOLITI C, NEUMANN J: Octreotide inthe management of diarrhea induced by graft versus host disease. Oncology Nursing Forum (1998) 25:873–878.
   PubMedGoogle Scholar
• TURTEL P, ROUHEED M: Continuous subcutaneous octreotide infusion for the treatment of severe diarrhea in Crohn's disease. Am. J. Gastroenterol. (1999) 94:P2740.
   Google Scholar
• RIPAMONTI C, MERCADANTE S, GROFF Let al.: Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J. Pain Symptom Manage. (2000) 19:23–34.
   Google Scholar
• PERLEMUTER G, CACOUB P, CHAUSSADE S et al.: Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum. (1999) 42:1545–9.
   PubMed Web of Science ®Google Scholar
• LEMBCKE B, CREUTZFELDT W, SCHLESER S et al.: Effect of the somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal pancreatic and biliary function and hormone release in normal men. Digestion (1987) 36:108–124.
   PubMed Web of Science ®Google Scholar
• HALMA C, JANSEN JB, JANSSENS R et al.: Life-threatening water intoxication during somatostatin therapy. Ann. Intern. Med. (1987) 107:518–529.
   PubMedGoogle Scholar
• POP-BUSUI R, CHEY W, STEVENS MJ:Severe hypertension induced by long-acting somatostatin analogue Sandostatin LAR in a patient with diabetic autonomic neuropathy. j Clin. Endocrinol. Metab. (2000) 85:943–946.
   PubMedGoogle Scholar
• DOWLING RH, HUSSAINI SH, MURPHY GM et al.: Gallstones during octreotide therapy. Ann. Intern. Med. (1987) 107:518–529.
   PubMedGoogle Scholar
• TRENDLE MC, MOERTEL CG, KVOLS LK: Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic and malignant islet cell tumours. Cancer (1997) 79:830–834.
   PubMed Web of Science ®Google Scholar
• MARKI F, BUTCHER UM, RICHTER JC: Multiple subcutaneous injections of somatostatin induce tachyphylaxis of the suppression of plasma insulin but not glucagon, in the rat. Regul. Pept. (1982) 4:333–339.
   PubMedGoogle Scholar
• LAMBERTS SWJ, REUBI JC, UITTERLINDEN P et al.: Studies on themechanism of action of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumour 7315a. Endocrinology (1986) 118:2188–2194.
   PubMedGoogle Scholar
• KLIJN JGM, SETYONO-HAN B, BAKKER GH. Prophylactic neuropeptide-analog treatment of a transplantable pancreatic tumour in rats. Progress in Cancer Res. and Therapy (1988) 35:350.
   Google Scholar
• SIEGEL RA, TOLCSVAI L, RUDIN M: Partial inhibition of the growth of transplanted Dunning rat prostate tumours with the long-acting somatosatin analog Sandostatin (SMS 201-995). Cancer Res. (1988) 48:4651–4655.
   PubMed Web of Science ®Google Scholar
• HIPKIN RW, FRIEDMAN J, CLAR RB et al.: Agonist-induced desensitization, internalization and phosphorylation of the sst2A somatostatin receptor./ Biol. Chem. (1997) 272:13867–13876.
   Google Scholar
• BEAUMONT V, HEPWORTH MB, LUTY JS et al.: Somatostatin receptor desensitization in NG108-15 cells. A consequence of receptor sequestration. J Biol. Chem. (1998) 273:33174–33183.
   PubMedGoogle Scholar
• ESCORSELL A, BANDI JC, ANDREU V et al.: Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 120:161–169.
   PubMed Web of Science ®Google Scholar
• KISKER O, BASTIAN D, BARTSCH D et al.: Localization, malignant potential and surgical management of gastrinomas. World J. Surg. (1998) 22:651–657.
   PubMedGoogle Scholar
• ARNOLD R, NEUHAUS C, BENNING R et al.: Somatostatin analog Sandostatin and inhibition of tumour growth in patients with metastatic endocrine gastroenteropancreatic tumours. World J. Surg. (1993) 17:511–519.
   PubMed Web of Science ®Google Scholar
• ARNOLD R, SIMON B, WIED M: Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion (2000) 62\(Suppl. 1):84–91.
   Google Scholar
• ••In depth review on the antiproliferativepotency of somatostatin analogues.
   Google Scholar
• TAYLOR JE, BOGDEN AE, MOREAU JP, COY DH: In vitro inhibition of human small cell lung carcinoma (NCL-H69) growth by somatostatin analogue Biochem. Biophys. Res. Commun. (1988) 153:81–86.
   PubMed Web of Science ®Google Scholar
• SIEGEL RA, TOLSCAVAI L, RUDIN M: Partial inhibition of the growth of transplanted Dunning rat prostate tumours with the long-acting somatostatin analogue Sandostatin (SMS 201-995). Cancer Res. (1988) 153:4651–4655.
   Google Scholar
• LIEBOW C, REILLY C, SERRANO M, SCHALLY AV: Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc. Natl. Acad. Sci. USA (1989) 86:2001–2007.
   Google Scholar
• SHEPHARD JJ, SENATOR GB: Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201–995. Lancet (1986) ii:574.
   Google Scholar
• WIEDENMANN B, RATH U, RADSCH R et al.: Tumour regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995. Klin Wochenschr (1988) 66:75–77.
   PubMedGoogle Scholar
• KRAENZLIN ME, CHNG JC, WOOD SM, BLOOM SR: Can inhibition of hormone secretion be associated with endocrine tumour shrinkage? Lancet (1983) ii:1501–1504.
   Google Scholar
• CLEMENTS D, ELIAS E: Regression of metastatic VIPoma with somatostatin analogue SMS 201–995. Lancet (1985) i:874–875.
   Google Scholar
• IMTIAZ KE, MONTEITH P, KHALEELI A: Complete histological regression of metastatic carcinoid tumour: treatment with octreotide. Clin. Endocrinol. (2000) 53:755–758.
   PubMedGoogle Scholar
• FILOSSO PL, CROCE S, OLIARO A and RAFFINI E: Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung. J Cardiovasc. Surg (2000) 41:773–776.
   PubMedGoogle Scholar
• SALTZ L, TROCHANOWSKY G, BUCKLEY M et al.: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumours. Cancer (1993) 72:244–248.
   PubMed Web of Science ®Google Scholar
• DI BARTOLOMEO M, BAJETTA E, BUZZONI R et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumours. Cancer (1996) 77:402–408.
   PubMed Web of Science ®Google Scholar
• ERIKSSON B, RENSTRUP J, IMAN H, OBERG K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours: Clinical and biological effects. Ann. Oncol. (1997) 8:1041–1044.
   PubMed Web of Science ®Google Scholar
• FAISS S, RATH U, MANSMANN U et al.: Ultrahigh dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumours. Digestion (1999) 60:469–476.
   PubMed Web of Science ®Google Scholar
• DUCREUX M, RUSZNIEWSKI PH, CHAYVIALLE JA et al.: The antitumoural effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumours. Am. J. Gastroenterol. (2000) 95:3276–3281.
   PubMed Web of Science ®Google Scholar
• GORDON PH: NIH Conference: Somatostatin and somatostatin analogue (SMS 201-995) in the treatment of hormone-secreting tumours of the pituitary and gastrointestinal tract and nonneoplastic diseases of the gut. Ann. Intern. Med. (1989) 110:35–50.
   PubMedGoogle Scholar
• APARICIO T, DUCREUX M, BAUDIN E et al.: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. j Cancer (2001) 37:1014–1019.
   PubMed Web of Science ®Google Scholar
• JOENSUN H, KATKA K, KUJARI H: Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol. (Copenhagen) (1992) 126:184–185.
   PubMedGoogle Scholar
• JANSON ET, OBERG K: Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. (1993) 32:225–229.
   Google Scholar
• FRANK M, KLOSE KJ, WIED Met al.: Combination therapy with octreotide and a-interferon: Effect of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Am. J Gastroenterol. (1999) 94:1382–1387.
   Google Scholar
• ALBERT R, SMITH-JONES P, STOLZ B et al.: Direct synthesis of [DOTA-Dphel]-octreotide and [DOTA-Dphe1-Tyr-3]-octreotide (5MT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumours in man. Bioorg. Med. Chem. Lett. (1998) 8:1207–1210.
   PubMed Web of Science ®Google Scholar
• STOLZ B, WECKBECKER G, SMITH-JONES P et al.: The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-Dphe1-Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur. Nuc. Med. (1998) 25:668–674.
   PubMedGoogle Scholar
• SMITH-JONES P, STOLZ B, ALBERT R et al.: Synthesis and characterisation of [90Y]-Bz-DTPA-octreotide: a Yttrium-90-labelled octreotide analogue for radiotherpy of somatostatin receptor-positive tumours. Nuc. Med. Biol. (1998) 25:181–188.
   PubMedGoogle Scholar
• BAKKER WH, ALBERT R, BRUNS C et al.: [1111n-DTPA-D-Phe 1] -octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabelling and in vitro validation. Lifi Sci. (1991) 49:1583–1591.
   PubMed Web of Science ®Google Scholar
• SLOOTER GD, BREEMAN WAP, MARQUET RL et al.: Antiproliferative effect of radiolabelled octreotide in a metastases model in rat liver. International Journal of Cancer (1999) 81:767–771.
   PubMedGoogle Scholar
• STOLZ B, BRUNS C, ALBERT R et al.: Somatostatin receptor-targeted radiotherapy - preclinical proof of concept. In: Octreotide: The Next Decade. SWS Lamberts (Ed.), Bioscientifica Ltd Bristol (1999):39–47.
   Google Scholar
• KRENNING EP, VALKEMA R, KOOIJ PPM et al.: Scintigraphy and radionuclide therapy with [Indium-111-labelled-diethyl triarnine penta-acetic acid-D-Phel]-octreotide. Ital. J. Gastroenterol. Hepatol. (1999) 31\(Supp1.2):219–23.
   Google Scholar
• TIENSUU JANSON E, ERIKSSON B, OBERG K et al.: Treatment with high dose [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumours. Acta Oncol. (1999) 38:373–377.
   PubMed Web of Science ®Google Scholar
• PAGANELI G, ZOBOLI S, CREMONES M et al.: Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur. J. Nucl. Med. (2001) 28:426–434.
   PubMedGoogle Scholar
• OTTE A, HERRMANN R, HEPPELER A et al.: Yttrium-90 DOTATOC: first clinical results. Eur. J. Nucl. Med. (1999) 26:1439–1447.
   PubMedGoogle Scholar
• WALDHERR C, PLESS M, MAECKE HR et al.: The clinical value of [90Y-DOTN-D-Phe1-Tyr-3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical Phase II study. Ann. Oncol. (2001) 12:941–945.
   PubMed Web of Science ®Google Scholar
• •First full report on the efficacy of radioligand therapy in patients with endocrine malignancies with follow-up observations.
   Google Scholar
• BREEMAN WAP, DE JONG M, KWEKKEBOOM DJ et al.: Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. Nucl. Med. (2001) 28:1421–1429.
   Google Scholar
• MOLL S, NICKELEIT V, MUELLER-BRAND J et al.: A new cause of renal thyrombotic microangiopathy: Yttrium-90-DOTATOC internal radiotherapy. Am. J. Kidney Dis. (2001) 37:847–851.
   PubMed Web of Science ®Google Scholar
• BEHR TM, BEHE M, KLUGE G et al.: Nephrotoxicity versus antitumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eu. j Nul. Med. (2002) 29:277–279.
   Google Scholar
• BEHR TM, SHARKEY RM, JUWEID ME et al.: Reduction of the renal uptake of radiolabelled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. (1995) 55:3825–3834.
   PubMed Web of Science ®Google Scholar
• BEHR TM, SHARKEY RM, SGOUROS G et al.: Overcoming the nephrotoxicity of radiometal-labelled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer (1997) 80:2591–2610.
   PubMed Web of Science ®Google Scholar
• WYMENGA AN, ERIKSSON B, SALMELA PI et al.: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumours and hormone-related symptoms. J. Clin. Oncol. (1999) 17(4):1111.
   PubMed Web of Science ®Google Scholar
• SAVEANU A, GUNZ G, D'UFO'UR H et al.: BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin. Endocrinol. Metab. (2001) 86(1):140.
   Google Scholar
• •Description of a new sst2- and sst5-bispecific compound with higher potency to suppress growth hormone secretion from adenomas than octreotide.
   Google Scholar
• NAGY A, SCHALLY AV, HALMOS Get al.: Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. (1998) 95:1794–1799.
   Google Scholar
• •First description of synthesis and evaluation of cytotoxic somatostatin analogs containing doxorubicin.
   Google Scholar
• SCHALLYAV, COMARU-SCHALLYAM, NAGY A et al.: Hypothalamic hormones and cancer. Frontiers Neuroendocr (2001) 22:248–291.
   PubMedGoogle Scholar
• •An in-depth review on cytotoxic analogs of somatostatin, bombesin and LH-RH.
   Google Scholar